These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 34449906)

  • 21. [Ocular symptoms associated with dupilumab in atopic dermatitis].
    Voorberg AN; Oosterhaven JAF; Wijdh RHJ; de Bruin-Weller MS; Schuttelaar MLA
    Ned Tijdschr Geneeskd; 2019 Mar; 163():. PubMed ID: 30945835
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dupilumab-associated hypereosinophilia in patients treated for moderate-to-severe atopic dermatitis.
    Marcant P; Balayé P; Merhi R; Jendoubi F; Nosbaum A; Raison-Peyron N; Du-Thanh A; Lasek A; Ferrier le Bouedec MC; Tetart F; Valois A; Barbarot S; Soria A; Jachiet M; Staumont-Sallé D;
    J Eur Acad Dermatol Venereol; 2021 Jun; 35(6):e394-e396. PubMed ID: 33594731
    [No Abstract]   [Full Text] [Related]  

  • 23. Real-world evidence of dupilumab efficacy and risk of adverse events: A systematic review and meta-analysis.
    Halling AS; Loft N; Silverberg JI; Guttman-Yassky E; Thyssen JP
    J Am Acad Dermatol; 2021 Jan; 84(1):139-147. PubMed ID: 32822798
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dupilumab facial redness: Clinical characteristics and proposed treatment in a cohort.
    Ordóñez-Rubiano MF; Casas M; Balaguera-Orjuela V
    Dermatol Ther; 2021 Nov; 34(6):e15140. PubMed ID: 34549488
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dupilumab for the Treatment of Atopic Dermatitis.
    Ferreira S; Torres T
    Actas Dermosifiliogr (Engl Ed); 2018 Apr; 109(3):230-240. PubMed ID: 29422431
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fifty-two week follow-up safety and effectiveness results of dupilumab treatment of moderate-to-severe atopic dermatitis from a retrospective, multicentric series.
    Ruiz-Villaverde R; Dominguez-Cruz J; Armario-Hita JC; Martinez-Pilar L; Alcantara-Luna S; Pereyra-Rodriguez JJ
    Dermatol Ther; 2019 Jul; 32(4):e12931. PubMed ID: 30980485
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dupilumab ocular surface disease occurs predominantly in patients receiving dupilumab for atopic dermatitis: A multi-institution retrospective chart review.
    Waldman RA; DeWane ME; Sloan SB; King B; Grant-Kels JM
    J Am Acad Dermatol; 2021 Sep; 85(3):735-736. PubMed ID: 31325553
    [No Abstract]   [Full Text] [Related]  

  • 28. Dupilumab use in atopic dermatitis and beyond in skin diseases.
    Fourzali K; Golpanian RS; Yosipovitch G
    Immunotherapy; 2020 Dec; 12(17):1221-1235. PubMed ID: 32892674
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Acute onset of psoriasis in a patient with atopic dermatitis treated with dupilumab.
    Ferrucci S; Tavecchio S; Berti E; Angileri L
    Clin Exp Dermatol; 2020 Jul; 45(5):625-626. PubMed ID: 32112580
    [No Abstract]   [Full Text] [Related]  

  • 30. New insights on ocular surface disease in patients with atopic dermatitis treated with dupilumab.
    Bortoluzzi P; Ferrucci S; Galimberti D; Garavelli F; Pozzo Giuffrida F; Pizzati A; Marzano AV; Mapelli C
    Br J Dermatol; 2022 Jan; 186(1):186-187. PubMed ID: 34431510
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Psoriasis in dupilumab-treated atopic dermatitis].
    Senner S; Eicher L; Aszodi N; Prinz JC; French LE; Wollenberg A
    Hautarzt; 2020 May; 71(5):383-386. PubMed ID: 32179945
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dupilumab in HIV-positive patients with atopic dermatitis: a long-term follow-up patient and a literature review.
    Avallone G; Trunfio M; Giura MT; Siliquini N; Viola R; Orofino G; Mastorino L; Ortoncelli M; Quaglino P; Ribero S
    Dermatol Online J; 2021 Aug; 27(8):. PubMed ID: 34755964
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Facial and neck erythema associated with dupilumab treatment: A systematic review.
    Jo CE; Finstad A; Georgakopoulos JR; Piguet V; Yeung J; Drucker AM
    J Am Acad Dermatol; 2021 May; 84(5):1339-1347. PubMed ID: 33428978
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Improvement of alopecia areata with Dupilumab in a patient with severe atopic dermatitis and review the literature.
    Magdaleno-Tapial J; Valenzuela-Oñate C; García-Legaz-Martínez M; Martínez-Domenech Á; Pérez-Ferriols A
    Australas J Dermatol; 2020 May; 61(2):e223-e225. PubMed ID: 31766073
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Superimposed linear atopic dermatitis treated with dupilumab.
    Leszczynska MA; Trainor MA; Henkel E; Keeling BH; Diaz LZ
    Pediatr Dermatol; 2021 Sep; 38(5):1377-1378. PubMed ID: 34272754
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dupilumab-Induced Facial Flushing After Alcohol Consumption.
    Brownstone ND; Reddy V; Thibodeaux Q; Myers B; Chan S; Liao W; Bhutani T
    Cutis; 2021 Aug; 108(2):106-107. PubMed ID: 34735321
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recurrence of conjunctival goblet cells after discontinuation of dupilumab in a patient with dupilumab-related conjunctivitis.
    Voorberg AN; den Dunnen WFA; Wijdh RHJ; de Bruin-Weller MS; Schuttelaar MLA
    J Eur Acad Dermatol Venereol; 2020 Feb; 34(2):e64-e66. PubMed ID: 31465590
    [No Abstract]   [Full Text] [Related]  

  • 38. Chronic inflammatory demyelinating polyneuropathy after commencement of dupilumab for atopic dermatitis: Coincidence or contributory?
    Lee AYS; Hannaford A; Vucic S; Berglund LJ
    Ann Allergy Asthma Immunol; 2022 Jan; 128(1):105-106. PubMed ID: 34481048
    [No Abstract]   [Full Text] [Related]  

  • 39. Real-world experience of dupilumab treatment for atopic dermatitis in adults: a retrospective analysis of patients' records.
    Wang C; Kraus CN; Patel KG; Ganesan AK; Grando SA
    Int J Dermatol; 2020 Feb; 59(2):253-256. PubMed ID: 31286499
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reasons for discontinuation of dupilumab in adult atopic dermatitis in clinical practice.
    Marniquet ME; Seneschal J; Darrigade AS; Staumont-Sallé D; Jachiet M; Nosbaum A; Tauber M; Abasq C; Ferrier Le Bouedec MC; Droitcourt C; Aubert H; Bernier C; Soria A; Raison-Peyron N; Tétart F; Aubin F; Viguier M; Valois A; Kupfer-Bessaguet I; Goronflot T; Barbarot S;
    Br J Dermatol; 2022 Apr; 186(4):733-735. PubMed ID: 34748654
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.